Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Rapid Response Innovation Awards, 2009
    The Role of Casein Kinase 2 in the Modulation of Dopamine Signaling in Parkinson's Disease

    Objective/Rationale:
    Parkinson’s disease is caused by a selective loss of cells in the brain that produce the neurotransmitter dopamine. The major treatment for PD is Levodopa (L-Dopa) which gets...

  • Target Validation, 2009
    The Transcription Factor Nrf2 as a Target to Reduce Neurodegeneration and Neuroinflammation in Parkinson's Disease

    Objective/Rationale:
    Dopaminergic neuron loss and exacerbated neuroinflammation are events tightly involved in PD pathology that may result from an inadequate response to toxic, oxidant or inflammatory...

  • Target Validation, 2009
    Neuroprotection by PXDNL, a Novel Heme-containing Peroxidase

    Objective/Rationale:
    Dysfunction of mitochondria in nerve cells contributes to the neurodegeneration of PD. When cells are infected by the CMV virus, they become resistant to certain mitochondrial...

  • Target Validation, 2009
    Validation of Nox1/Rac1, a Novel Molecular Source of Reactive Oxygen Species in the Nigrostriatal Pathway, as a Target for Parkinson's Disease Therapy

    Objective/Rationale:
    A family of NADPH oxidase (NOX) is the specialized enzyme complex which generates superoxide. We demonstrate that Nox1, a NOX homologue, is upregulated in DA cells under various...

  • Target Validation, 2009
    Pharmacological Regulation of Endogenous GDNF Expression in the Adult Brain

    Objective/Rationale:
    GDNF is a potent trophic factor for dopamine neurons in the adult brain. Exogenous GDNF supplementation strategies, however, are fraught with technical difficulties associated with...

  • Target Validation, 2009
    The Polo Like Kinases (PLK2 and PLK3) as Therapeutic Targets for Parkinson's Disease

    Objective/Rationale:
    Phosphorylation of alpha-synuclein at serine 129 is characteristic of Parkinson's disease (PD) and related alpha-synulceinopathies. Unraveling the role of phosphorylation in...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.